A61K 39/285
Vaccinia virus or variola virus
A61K39/285 (Vaccinia virus or variola virus) appears on 190 US grants and 254 published applications in this corpus.
Search patents in A61K- Granted patents
- 190
- Published applications
- 254
- Assignees
- 131
- Inventors
- 364
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 4 | 0 |
| 2002 | 0 | 2 |
| 2003 | 2 | 7 |
| 2004 | 3 | 2 |
| 2005 | 2 | 8 |
| 2006 | 5 | 10 |
| 2007 | 2 | 14 |
| 2008 | 6 | 8 |
| 2009 | 7 | 18 |
| 2010 | 8 | 21 |
| 2011 | 19 | 22 |
| 2012 | 16 | 12 |
| 2013 | 14 | 14 |
| 2014 | 10 | 12 |
| 2015 | 10 | 10 |
| 2016 | 10 | 5 |
| 2017 | 6 | 15 |
| 2018 | 12 | 8 |
| 2019 | 8 | 7 |
| 2020 | 7 | 12 |
| 2021 | 7 | 12 |
| 2022 | 5 | 5 |
| 2023 | 3 | 12 |
| 2024 | 5 | 8 |
| 2025 | 5 | 3 |
| 2026 | 3 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Conditions improving poxvirus stability9 Jun 2026US 12,648,992 B2Bavarian Nordic A/S
- Smallpox vaccine for cancer treatment26 May 2026US 12,636,361 B2Calidi Biotherapeutics (Nevada), Inc.
- Synthetic chimeric vaccinia virus20 Jan 2026US 12,529,036 B2Tonix Pharma Limited
- Oncolytic vaccinia virus with modified B5R gene for the treatment of cancer30 Dec 2025US 12,509,704 B2Queen Mary University of London
- Use of triplex CMV vaccine in CAR T cell therapy25 Nov 2025US 12,478,672 B2City of Hope
- Methods of Isolating Poxviruses from Avian Cell Cultures27 Aug 2026US 2026/0248906 A1Bavarian Nordic A/S
- Pharmaceutical compositions, vaccines and their uses in the prevention or treatment of a persistent infection or of cancer23 Jul 2026US 2026/0207735 A1Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof21 May 2026US 2026/0137773 A1ViroMissile, Inc.
- Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof9 Apr 2026US 2026/0097116 A1ViroMissile, Inc.
- Nanoparticle-derived vaccines against poxviruses, and methods for making and using the same12 Mar 2026US 2026/0069682 A1The United States of America as Represented by the Secretary of the Department of Health and Human S
Most cited
By later US patents
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Microorganisms for therapy104US 7,588,767 B2Genelux Corporation · 2009
- Modified vaccinia ankara virus variant99US 6,761,893 B2Bavarian Nordic A/S · 2004
- Microorganisms for therapy98US 7,754,221 B2Genelux Corporation · 2010
- Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen89US 6,265,189 B1Virogenetics Corporation · 2001